Mizoribine serum levels associated with enterotoxicity in the dog
To prevent or minimize mizoribine enterotoxicity in organ transplant recipients and to differentiate mizoribine enterotoxicity from other causes of enteritis, serum levels of mizoribine that produced subclinical and clinical signs of enterotoxicity were determined in the dog. When mizoribine was adm...
Gespeichert in:
| Veröffentlicht in: | Transplantation 1991-04, Vol.51 (4), p.877-881 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 881 |
|---|---|
| container_issue | 4 |
| container_start_page | 877 |
| container_title | Transplantation |
| container_volume | 51 |
| creator | GREGORY, C. R GOURLEY, I. M CAIN, G. R PATZ, J. D IMONDI, K. A MARTIN, J. A |
| description | To prevent or minimize mizoribine enterotoxicity in organ transplant recipients and to differentiate mizoribine enterotoxicity from other causes of enteritis, serum levels of mizoribine that produced subclinical and clinical signs of enterotoxicity were determined in the dog. When mizoribine was administered orally at 12-hr intervals, half the dogs studied showed clinical evidence of gastrointestinal disturbances (vomiting, diarrhea, and anorexia) without histopathologic signs of enterotoxicity. Using a 24-hr oral-dose schedule, clinical signs of gastrointestinal disturbances and histopathologic evidence (mucosal degeneration, crypt degeneration, and necrosis) of enterotoxicity were encountered when the mean 12-hr mizoribine serum level was 0.97 +/- 0.4 microgram/ml or greater. Histopathologic signs of enterotoxicity with repeated positive fecal occult blood assays and without clinical signs of gastrointestinal disturbances occurred when the mean 12-hr serum level was 0.53 +/- 0.17 microgram/ml or greater. Oral administration of cyclosporine did not exacerbate mizoribine enterotoxicity in the dog when administered with mizoribine at a dose that produced histopathologic signs of enterotoxicity. |
| doi_str_mv | 10.1097/00007890-199104000-00027 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00007890_199104000_00027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2014547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-cfe1e1a70d008e8bdda7f687156e8adb5c9f37d8cd699f9d7b33e08b5c5c25cc3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EKqXwCUjesDSM6zi2l1XFSypiA-vIsSfUKE0qO-X19Rhaykij0cydexeHEMrhkoNRV5BLaQOMG8OhyBvLPVUHZMylKFgJGg7JGKDgjAuhjslJSq_5RQqlRmQ0BV7IQo3J7CF89THUoUOaMG5WtMU3bBO1KfUu2AE9fQ_DkmI3YOyH_iO4MHzS0NFhidT3L6fkqLFtwrPdnJDnm-un-R1bPN7ez2cL5oSBgbkGOXKrwANo1LX3VjWlVlyWqK2vpTONUF47XxrTGK9qIRB0vks3lc6JCdHbXBf7lCI21TqGlY2fFYfqB0r1B6XaQ6l-oWTr-da63tQr9HvjjkLWL3a6Tc62TbSdC-k_3yhpcrL4BgNQaxI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mizoribine serum levels associated with enterotoxicity in the dog</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>GREGORY, C. R ; GOURLEY, I. M ; CAIN, G. R ; PATZ, J. D ; IMONDI, K. A ; MARTIN, J. A</creator><creatorcontrib>GREGORY, C. R ; GOURLEY, I. M ; CAIN, G. R ; PATZ, J. D ; IMONDI, K. A ; MARTIN, J. A</creatorcontrib><description>To prevent or minimize mizoribine enterotoxicity in organ transplant recipients and to differentiate mizoribine enterotoxicity from other causes of enteritis, serum levels of mizoribine that produced subclinical and clinical signs of enterotoxicity were determined in the dog. When mizoribine was administered orally at 12-hr intervals, half the dogs studied showed clinical evidence of gastrointestinal disturbances (vomiting, diarrhea, and anorexia) without histopathologic signs of enterotoxicity. Using a 24-hr oral-dose schedule, clinical signs of gastrointestinal disturbances and histopathologic evidence (mucosal degeneration, crypt degeneration, and necrosis) of enterotoxicity were encountered when the mean 12-hr mizoribine serum level was 0.97 +/- 0.4 microgram/ml or greater. Histopathologic signs of enterotoxicity with repeated positive fecal occult blood assays and without clinical signs of gastrointestinal disturbances occurred when the mean 12-hr serum level was 0.53 +/- 0.17 microgram/ml or greater. Oral administration of cyclosporine did not exacerbate mizoribine enterotoxicity in the dog when administered with mizoribine at a dose that produced histopathologic signs of enterotoxicity.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-199104000-00027</identifier><identifier>PMID: 2014547</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Animals ; Biological and medical sciences ; Cyclosporins - administration & dosage ; Cyclosporins - pharmacology ; Dogs ; Drug Synergism ; Drug toxicity and drugs side effects treatment ; Enteritis - chemically induced ; Female ; Graft Survival ; Immunosuppressive Agents - toxicity ; Intestines - drug effects ; Kidney Transplantation - immunology ; Kidney Transplantation - physiology ; Medical sciences ; Pharmacology. Drug treatments ; Ribonucleosides - blood ; Ribonucleosides - toxicity ; Toxicity: digestive system ; Transplantation, Homologous</subject><ispartof>Transplantation, 1991-04, Vol.51 (4), p.877-881</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-cfe1e1a70d008e8bdda7f687156e8adb5c9f37d8cd699f9d7b33e08b5c5c25cc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19759078$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2014547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GREGORY, C. R</creatorcontrib><creatorcontrib>GOURLEY, I. M</creatorcontrib><creatorcontrib>CAIN, G. R</creatorcontrib><creatorcontrib>PATZ, J. D</creatorcontrib><creatorcontrib>IMONDI, K. A</creatorcontrib><creatorcontrib>MARTIN, J. A</creatorcontrib><title>Mizoribine serum levels associated with enterotoxicity in the dog</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>To prevent or minimize mizoribine enterotoxicity in organ transplant recipients and to differentiate mizoribine enterotoxicity from other causes of enteritis, serum levels of mizoribine that produced subclinical and clinical signs of enterotoxicity were determined in the dog. When mizoribine was administered orally at 12-hr intervals, half the dogs studied showed clinical evidence of gastrointestinal disturbances (vomiting, diarrhea, and anorexia) without histopathologic signs of enterotoxicity. Using a 24-hr oral-dose schedule, clinical signs of gastrointestinal disturbances and histopathologic evidence (mucosal degeneration, crypt degeneration, and necrosis) of enterotoxicity were encountered when the mean 12-hr mizoribine serum level was 0.97 +/- 0.4 microgram/ml or greater. Histopathologic signs of enterotoxicity with repeated positive fecal occult blood assays and without clinical signs of gastrointestinal disturbances occurred when the mean 12-hr serum level was 0.53 +/- 0.17 microgram/ml or greater. Oral administration of cyclosporine did not exacerbate mizoribine enterotoxicity in the dog when administered with mizoribine at a dose that produced histopathologic signs of enterotoxicity.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cyclosporins - administration & dosage</subject><subject>Cyclosporins - pharmacology</subject><subject>Dogs</subject><subject>Drug Synergism</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Enteritis - chemically induced</subject><subject>Female</subject><subject>Graft Survival</subject><subject>Immunosuppressive Agents - toxicity</subject><subject>Intestines - drug effects</subject><subject>Kidney Transplantation - immunology</subject><subject>Kidney Transplantation - physiology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Ribonucleosides - blood</subject><subject>Ribonucleosides - toxicity</subject><subject>Toxicity: digestive system</subject><subject>Transplantation, Homologous</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRS0EKqXwCUjesDSM6zi2l1XFSypiA-vIsSfUKE0qO-X19Rhaykij0cydexeHEMrhkoNRV5BLaQOMG8OhyBvLPVUHZMylKFgJGg7JGKDgjAuhjslJSq_5RQqlRmQ0BV7IQo3J7CF89THUoUOaMG5WtMU3bBO1KfUu2AE9fQ_DkmI3YOyH_iO4MHzS0NFhidT3L6fkqLFtwrPdnJDnm-un-R1bPN7ez2cL5oSBgbkGOXKrwANo1LX3VjWlVlyWqK2vpTONUF47XxrTGK9qIRB0vks3lc6JCdHbXBf7lCI21TqGlY2fFYfqB0r1B6XaQ6l-oWTr-da63tQr9HvjjkLWL3a6Tc62TbSdC-k_3yhpcrL4BgNQaxI</recordid><startdate>19910401</startdate><enddate>19910401</enddate><creator>GREGORY, C. R</creator><creator>GOURLEY, I. M</creator><creator>CAIN, G. R</creator><creator>PATZ, J. D</creator><creator>IMONDI, K. A</creator><creator>MARTIN, J. A</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19910401</creationdate><title>Mizoribine serum levels associated with enterotoxicity in the dog</title><author>GREGORY, C. R ; GOURLEY, I. M ; CAIN, G. R ; PATZ, J. D ; IMONDI, K. A ; MARTIN, J. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-cfe1e1a70d008e8bdda7f687156e8adb5c9f37d8cd699f9d7b33e08b5c5c25cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cyclosporins - administration & dosage</topic><topic>Cyclosporins - pharmacology</topic><topic>Dogs</topic><topic>Drug Synergism</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Enteritis - chemically induced</topic><topic>Female</topic><topic>Graft Survival</topic><topic>Immunosuppressive Agents - toxicity</topic><topic>Intestines - drug effects</topic><topic>Kidney Transplantation - immunology</topic><topic>Kidney Transplantation - physiology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Ribonucleosides - blood</topic><topic>Ribonucleosides - toxicity</topic><topic>Toxicity: digestive system</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GREGORY, C. R</creatorcontrib><creatorcontrib>GOURLEY, I. M</creatorcontrib><creatorcontrib>CAIN, G. R</creatorcontrib><creatorcontrib>PATZ, J. D</creatorcontrib><creatorcontrib>IMONDI, K. A</creatorcontrib><creatorcontrib>MARTIN, J. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GREGORY, C. R</au><au>GOURLEY, I. M</au><au>CAIN, G. R</au><au>PATZ, J. D</au><au>IMONDI, K. A</au><au>MARTIN, J. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mizoribine serum levels associated with enterotoxicity in the dog</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>1991-04-01</date><risdate>1991</risdate><volume>51</volume><issue>4</issue><spage>877</spage><epage>881</epage><pages>877-881</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>To prevent or minimize mizoribine enterotoxicity in organ transplant recipients and to differentiate mizoribine enterotoxicity from other causes of enteritis, serum levels of mizoribine that produced subclinical and clinical signs of enterotoxicity were determined in the dog. When mizoribine was administered orally at 12-hr intervals, half the dogs studied showed clinical evidence of gastrointestinal disturbances (vomiting, diarrhea, and anorexia) without histopathologic signs of enterotoxicity. Using a 24-hr oral-dose schedule, clinical signs of gastrointestinal disturbances and histopathologic evidence (mucosal degeneration, crypt degeneration, and necrosis) of enterotoxicity were encountered when the mean 12-hr mizoribine serum level was 0.97 +/- 0.4 microgram/ml or greater. Histopathologic signs of enterotoxicity with repeated positive fecal occult blood assays and without clinical signs of gastrointestinal disturbances occurred when the mean 12-hr serum level was 0.53 +/- 0.17 microgram/ml or greater. Oral administration of cyclosporine did not exacerbate mizoribine enterotoxicity in the dog when administered with mizoribine at a dose that produced histopathologic signs of enterotoxicity.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>2014547</pmid><doi>10.1097/00007890-199104000-00027</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 1991-04, Vol.51 (4), p.877-881 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00007890_199104000_00027 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Animals Biological and medical sciences Cyclosporins - administration & dosage Cyclosporins - pharmacology Dogs Drug Synergism Drug toxicity and drugs side effects treatment Enteritis - chemically induced Female Graft Survival Immunosuppressive Agents - toxicity Intestines - drug effects Kidney Transplantation - immunology Kidney Transplantation - physiology Medical sciences Pharmacology. Drug treatments Ribonucleosides - blood Ribonucleosides - toxicity Toxicity: digestive system Transplantation, Homologous |
| title | Mizoribine serum levels associated with enterotoxicity in the dog |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A10%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mizoribine%20serum%20levels%20associated%20with%20enterotoxicity%20in%20the%20dog&rft.jtitle=Transplantation&rft.au=GREGORY,%20C.%20R&rft.date=1991-04-01&rft.volume=51&rft.issue=4&rft.spage=877&rft.epage=881&rft.pages=877-881&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-199104000-00027&rft_dat=%3Cpubmed_cross%3E2014547%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2014547&rfr_iscdi=true |